卢洪洲

教授，博士生导师，美国微生物科学院院士

深圳市第三人民医院党委副书记、院长

联系方式：办公室电话: 0755-61232898

邮 箱: luhongzhou@fudan.edu.cn

       luhongzhou@szsy.sustech.edu.cn

研究方向：感染性疾病的诊治与发病机制研究

教学及科研情况

在复旦大学上海医学院开设《新发传染病》、《AIDS》全英文课程。

主要研究方向为感染性疾病的诊治与发病机制研究。先后承担：国家“十一五”、“十二五” 、“十三五”传染病重大专项、“十二五”和“十三五”新药创制平台、“863”、“973”（子课题）、国家自然科学基金（五项）；美国盖茨基金、美国NIH项目（二项）；国家临床重点专科、国家卫计委、上海市科委基金、上海市卫计委“公共卫生三年行动计划”（二项）等30余项科研课题。以第一作者或通讯作者在国内外发表各类论文400余篇，其中在SCI引用杂志包括《New England Journal of Medicine》、《Emerging Infectious Diseases》、《AIDS》、《Plos one》、《Journal of Clinical Microbiology》发表论著100余篇；已主编专业参考书12部。已获上海医学科技奖一等奖等10项省部级科技成果奖、获专利4项。先后入选：国家百千万人才工程、“有突出贡献中青年专家”、上海科技进步奖-科普人才、全国道德模范与身边好人（中国好医生）、科学中国人（2016）年度人物、“最美援外医生”、“影响中国”（2014年度）科技人物、第二届上海市“人道博爱奖”；“上海领军人才”、“上海市优秀学科带头人”、“上海市医学领军人才”、上海市“五一劳动奖章”获得者、上海市卫生系统 “银蛇奖”、 “仁心医者▪上海市杰出专科医师奖”、“医务工匠”、文明职工、“创新之星”、“优秀发明银奖”；上海市卫生局先进工作者并行政记大功一次、上海市科委“明治乳业科学奖”；美国肝病学会-亚太肝病学会奖、艾滋病国际倡导联盟“精忠奖”。

学术任职

深圳市第三人民医院党委副书记、院长。

深圳市首届疫情防控公共卫生专家组组长，教育部长江学者、国家百千万人才工程、“有突出贡献中青年专家”、享受国务院特殊津贴。入选美国斯坦福大学2021、 2022年全球前2％顶尖科学家榜单及《终身科学影响力排行榜》。

现任世界卫生组织新发传染病临床诊治培训研究合作中心共同主任；世界卫生组织临床专家组专家、国家卫生健康委疾病预防控制专家委员会委员；国家新冠病毒病救治专家组与境外抗疫专家组后方支持团队成员；国家卫生健康委艾滋病、（禽）流感、出血热、黄热病、寨卡病毒病、新型冠状病毒肺炎、感染病质量控制中心专家组成员；中国性病艾滋病防治协会学术委员会副主任委员兼艾滋病合并结核专业委员会主任委员、国家卫生健康委医药卫生科技发展研究中心临床医学专家委员会委员、国家医师资格考试临床类别试题开发专家委员会委员；国家卫生健康委能力建设和继续教育传染病学专家委员会委员。中华医学会热带病与寄生虫病学分会前任主任委员兼艾滋病学组组长、中华医学会感染病学分会艾滋病专业学组副组长、中华预防医学会医疗机构公共卫生管理分会副主任委员、中华医学会卫生学分会临床与预防学组委员；中华医学科技奖评审委员会委员；中国医院协会传染病医院分会副主任委员；全国艾滋病临床试验联盟召集人、国家抗艾滋病病毒药物工程技术研究中心委员、长江三角洲传染病防治医联体与艾滋病诊治创新联盟召集人；上海市医学会感染病学分会主任委员、上海市医师协会感染病学分会副主任委员、上海市预防医学会卫生专科学会副主任委员及艾滋病性病防治专业委员会理事兼副主任委员、上海市药学会理事兼药物治疗专业委员会副主任委员、上海市微生物学会医学真菌专业委员会副主任委员、上海市新发与再现传染病研究所副所长、上海公卫医师规范化培训专家委员会副主任委员、上海市呼吸病研究所学术委员会委员兼呼吸感染防治研究基地副主任；上海市健康管理研究会理事兼体检专业委员会主任委员；上海市突出贡献专家协会健康专业委员会主任委员、上海市艾滋病诊疗中心主任、上海市艾滋病治疗专家组组长、上海市艾滋病性病防治协会副秘书长、上海市母婴安全专家委员会委员；上海市（禽）流感、埃博拉、黄热病、寨卡病毒病临床专家组组长；复旦大学生命科学学院兼职教授；大熊猫国家公园珍稀动物保护生物学国家林业和草原局重点实验室学术委员会委员等；广东省临床研究质量控制中心委员；广东省临床医学学会感染精准诊疗专业委员会主任委员。

《Drug Discoveries& Therapeutics》杂志国际领域首席编辑和执行编辑；《AIDS中文版》杂志主编；《Radiology of Infectious Diseases》、《诊断学理论与实践》、《热带病与寄生虫学》、《微生物与感染》、《中国真菌学杂志》、《中华临床感染病杂志》、《新发传染病》副主编；《Chinese Journal of Medicine》、《Emerging Microbes and Infections》、《BioScience Trends》、《Infection International》、《Global Health & Medicine》、《中国抗感染与化疗杂志》、《中华传染病杂志》、《中国艾滋病性病》、《内科学理论与实践》、《临床内科杂志》、《中国抗生素杂志》、《世界临床药物》、《上海医药》等十余本杂志的编委。《The Lancet》、《Journal of Clinical Microbiology》、《Mycoses》等英文期刊审稿人。默克诊疗手册（第18、19、20版感染性疾病章节）主译。

近五年主要论文

1.Wang J, Li Q, Qiu Y, Lu H. COVID-19: imbalanced cell-mediated immune response drives to immunopathology[J]. Emerging Microbes & Infections. 2022,11(1):2393-2404.

2.Zhang P, Ren T, Lu H, et al. A feasibility study of Covid-19 detection using breath analysis by high-pressure photon ionization time-of-flight mass spectrometry[J]. Journal of Breath Research. 2022,16(4):10.

3.Yang Y, Gong X, Lu H, et al. Comparative neutralization profiles of naive and breakthrough infections with Delta, Omicron BA.1 and BA.2 variants of SARS-CoV-2[J]. Signal Transduction and Targeted Therapy. 2022,7(1):316.

4.Liu X, Zhu Z, Miao Q, Lim JW, Lu H. Monkeypox-A danger approaching Asia[J]. BioScience Trends. 2022,16(4):245-248.

5.Liu X, Zhu Z, Lu H, et al. Monkeypox claims new victims: the outbreak in men who have sex with men[J]. Infectious Diseases of Poverty. 2022,23;11(1):84.

6.Liu X, Wang H, Zhu Z, Zhang L, Cao J, Zhang L, Yang H, Wen H, Hu Y, Chen C, Lu H. Exploring bridge symptoms in HIV-positive people with comorbid depressive and anxiety disorders[J]. BMC Psychiatry. 2022,22(1):448.

7.Yi C, Ling Z, Lu X, Fu Y, Yang Z, Wangmo S, Chen S, Zhang Y, Ma L, Gu W, Lu H, Sun X, Sun B. A SARS-CoV-2 antibody retains potent neutralization against Omicron by targeting conserved RBM residues[J]. Cellular & Molecular Immunology. 2022,19(5):647-649.

8.Su B, Yao C, Lu H, et al. Long-acting HIV fusion inhibitor albuvirtide combined with ritonavir-boosted lopinavir for HIV-1-infected patients after failing the first-line antiretroviral therapy: 48-week randomized, controlled, phase 3 non-inferiority TALENT study[J]. The Journal of infection. 2022,85(3):334-363.

9.Li X, Wu L, Qu Y, Cao M, Feng J, Huang H, Liu Y, Lu H, Liu Q, Liu Y. Clinical characteristics and vaccine effectiveness against SARS-CoV-2 Omicron subvariant BA.2 in the children[J]. Signal Transduction and Targeted Therap. 2022,7(1):203.

10.Yang S, Ling Y, Lu H, et al. Hymecromone: a clinical prescription hyaluronan inhibitor for efficiently blocking COVID-19 progression[J]. Signal Transduction and Targeted Therap. 2022,7(1):91.

11.Hu J, Gu L, Lu H, et al. Long-term case-fatality rate of nontuberculous mycobacterial disease in people living with HIV[J]. Infectious Diseases of Poverty. 2022;11(1):16.

12.Liu D, Gu L, Zhang R, Liu L, Shen Y, Shao Y, Wang J, Sun J, Qi T, Wang Z, Tang Y, Song W, Xun J, Lu H, Chen J. Utility of urine lipoarabinomannan (LAM) in diagnosing mycobacteria infection among hospitalized HIV-positive patients[J]. International Journal of Infectious Diseases. 2022,118:65-70.

13.Li W, Yang S, Lu H, et al. SARS-CoV-2 RNA elements share human sequence identity and upregulate hyaluronan via NamiRNA-enhancer network[J]. EBioMedicine. 2022,76:103861.

14.YangYang, Gong X, Yang L, et al. Regular and booster vaccination with inactivated vaccines enhance the neutralizing activity against Omicron variant both in the breakthrough infections and vaccinees[J].  The Journal of infection. 2022,84(4):579-613.

15.Wang Y, Liu M, Lu H, et al. Novel sarbecovirus bispecific neutralizing antibodies with exceptional breadth and potency against currently circulating SARS-CoV-2 variants and sarbecoviruses[J].Cell Discovery. 2022;8(1):36.

16.Li Q, Wang L, Wang B, Lu H. The COVID-19-designated hospitals in China: preparing for public health emergencies[J]. Emerging Microbes & Infections. 2021,10(1):998-1001.

17.Chen J, Liu D, Yin L, Zhang L, Lu H. Can we use hydroxychloroquine to treat COVID-19 now? [J] International Journal of Antimicrobial Agents. 2021,57(1):106173.

18.Bao Y, Ling Y, Lu H, et al. Dynamic anti-spike protein antibody profiles in COVID-19 patients[J]. International Journal of Infectious Diseases. 2021,103:540-548.

19.Chen J, Zhang R, Lu H, et al. Clinical usefulness of metagenomic next-generation sequencing for the diagnosis of central nervous system infection in people living with HIV[J]. International Journal of Infectious Diseases. 2021;107:139-144.

20.Stratton CW, Tang YW, Lu H. Pathogenesis-directed therapy of 2019 novel coronavirus disease[J]. Journal of medical virology. 2021,93(3):1320-1342.

21.Meng X, Wang P, Xiong Y, Wu Y, Lin X, Lu S, Li R, Zhao B, Liu J, Zeng S, Zeng L, Wu Y, Lu Y, Zhang J, Liu D, Wang S, Lu H. Safety, tolerability, pharmacokinetic characteristics, and immunogenicity of MW33: a Phase 1 clinical study of the SARS-CoV-2 RBD-targeting monoclonal antibody[J]. Emerging Microbes & Infections. 2021,10(1):1638-1648.

22.Xie G, Ding F, Han L, Yin D, Lu H, Zhang M. The role of peripheral blood eosinophil counts in COVID-19 patients[J].Allergy. 2021,76(2):471-482.

23.Qiu C, Song Z, Wang J, Tian C, Liu X, Wu T, Li W, Zhang S, Lu H. Saliva specimen complements anal swab in assessing patients with COVID-19 for discharge from hospital[J]. Emerging Microbes & Infections. 2021,10(1):2090-2097.

24.Yi C, Sun X, Lin Y, Gu C, Ding L, Lu X, Yang Z, Zhang Y, Ma L, Gu W, Qu A, Zhou X, Li X, Xu J, Ling Z, Xie Y, Lu H, Sun B. Comprehensive mapping of binding hot spots of SARS-CoV-2 RBD-specific neutralizing antibodies for tracking immune escape variants[J]. Genome Medicine. 2021,13(1):164.

25. Tan Y, Zhang W, Zhu Z, Qiao N, Ling Y, Guo M, Yin T, Fang H, Xu X, Lu G, Zhang P, Yang S, Fu Z, Liang D, Xie Y, Zhang R, Jiang L, Yu S, Lu J, Jiang F, Chen J, Xiao C, Wang S, Chen S, Bian XW, Lu H, Liu F, Chen S. Integrating longitudinal clinical laboratory tests with targeted proteomic and transcriptomic analyses reveal the landscape of host responses in COVID-19[J]. Cell Discovery. 2021,7(1):42.

26. Li T, Lu H, Zhang W. Clinical observation and management of COVID-19 patients[J]. Emerging Microbes & Infections. 2020,9(1):687-690.

27.Feng Y, Ling Y, Bai T, Xie Y, Huang J, Li J, Xiong W, Yang D, Chen R, Lu F, Lu Y, Liu X, Chen Y, Li X, Li Y, Summah HD, Lin H, Yan J, Zhou M, Lu H, Qu J. COVID-19 with Different Severities: A Multicenter Study of Clinical Features[J]. American journal of respiratory and critical care medicine. 2020,201(11):1380-1388.

28.Chen J, Chen R, Shen Y, Wei H, Wang X, Zhang R, Hu Z, Xie R, Huang Q, Wang J, Liu L, Qi T, Wang Z, Song W, Tang Y, Sun J, Lu H. Efficacy and safety of lower dose tenofovir disoproxil fumarate and efavirenz versus standard dose in HIV-infected, antiretroviral-naive adults: a multicentre, randomized, noninferiority trial[J].Emerging Microbes & Infections. 2020,9(1):843-850.

29.Yi Z, Ling Y, Zhang X, Chen J, Hu K, Wang Y, Song W, Ying T, Zhang R, Lu H, Yuan Z. Functional mapping of B-cell linear epitopes of SARS-CoV-2 in COVID-19 convalescent population[J]. Emerging Microbes & Infections. 2020,9(1):1988-1996.

30. Zhang X, Tan Y, Ling Y, Lu G, Liu F, Yi Z, Jia X, Wu M, Shi B, Xu S, Chen J, Wang W, Chen B, Jiang L, Yu S, Lu J, Wang J, Xu M, Yuan Z, Zhang Q, Zhang X, Zhao G, Wang S, Chen S, Lu H. Viral and host factors related to the clinical outcome of COVID-19[J]. Nature. 2020,583(7816):437-440.

31. Chen J, Qi T, Liu L, Ling Y, Qian Z, Li T, Li F, Xu Q, Zhang Y, Xu S, Song Z, Zeng Y, Shen Y, Shi Y, Zhu T, Lu H. Clinical progression of patients with COVID-19 in Shanghai, China[J]. The Journal of infection. 2020,80(5):e1-e6.

32. Lu H, Stratton CW, Tang YW. An evolving approach to the laboratory assessment of COVID-19[J]. Journal of medical virology. 2020,92(10):1812-1817.

33.Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle[J]. Journal of medical virology. 2020,92(4):401-402.

34. Shen Y, Zheng F, Sun D, Ling Y, Chen J, Li F, Li T, Qian Z, Zhang Y, Xu Q, Liu L, Huang Q, Shan F, Xu L, Wu J, Zhu Z, Song Z, Li S, Shi Y, Zhang J, Wu X, Mendelsohn JB, Zhu T, Lu H. Epidemiology and clinical course of COVID-19 in Shanghai, China[J]. Emerging Microbes & Infections. 2020,9(1):1537-1545.

35.Liu XH, Lu SH, Chen J, Xia L, Yang ZG, Charles S, Yang Y, Lin Y, Lu HZ. Clinical characteristics of foreign-imported COVID-19 cases in Shanghai, China[J]. Emerging Microbes & Infections. 2020,9(1):1230-1232.

36.Lu H, Stratton CW, Tang YW. An evolving approach to the laboratory assessment of COVID-19[J]. Journal of medical virology. 2020,92(10):1812-1817.

37. Fu W, Liu Y, Xia L, Li M, Song Z, Hu H, Yang Z, Wang L, Cheng X, Wang M, Jiang R, Liu L, Mao X, Chen J, Ling Y, Zhang L, Yan J, Shan F, Steinhart C, Zhang X, Zhu T, Xu J, Lu H. A clinical pilot study on the safety and efficacy of aerosol inhalation treatment of IFN-κ plus TFF2 in patients with moderate COVID-19[J]. EClinicalMedicine. 2020,25:100478.

38. Lu H, Stratton CW, Tang YW. The Wuhan SARS-CoV-2-What's next for China[J]. Journal of medical virology. 2020,92(6):546-547.

39.Lu H, Tang YW. Myths in the laboratory diagnosis of HIV infection[J]. Emerging Microbes & Infections. 2019,8(1):1240-1242.

40.Yang J, Chen J, Ji Y, Tang Q, Zhang R, Liu L, Shen Y, Xun J, Song W, Tang Y, Wang Z, Qi T, Lu H. Lipid profile and renal safety of tenofovir disoproxil fumarate-based anti-retroviral therapy in HIV-infected Chinese patients[J]. International journal of infectious diseases. 2019,83:64-71.

41.Sun Y, Xu L, Zhang F, Song Z, Hu Y, Ji Y, Shen J, Li B, Lu H, Yang H. A promising magnetic SERS immunosensor for sensitive detection of avian influenza virus[J]. Biosensors and Bioelectronics. 2017,89(Pt 2):906-912.

42.Ji YJ, Liang PP, Shen JY, Sun JJ, Yang JY, Chen J, Qi TK, Wang ZY, Song W, Tang Y, Liu L, Zhang RF, Shen YZ, Lu HZ. Risk factors affecting the mortality of HIV-infected patients with pulmonary tuberculosis in the cART era: a retrospective cohort study in China[J]. Infectious Diseases of Poverty. 2018,7(1):25.

43.Ji Y, Zhang F, Zhang R, Shen Y, Liu L, Wang J, Yang J, Tang Q, Xun J, Qi T, Wang Z, Song W, Tang Y, Chen J, Lu H. Changes in intestinal microbiota in HIV-1-infected subjects following cART initiation: influence of CD4+ T cell count[J].  Emerging Microbes & Infections. 2018,7(1):113.